Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

Gilead Sciences

Status and phase: Completed; Phase 3

Conditions: Myocardial Ischemia

Treatments: Drug: Placebo; Drug: Ranolazine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00099788

MERLIN TIMI 36

CVT 3036

Details and patient eligibility

About

MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.

Full description

Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006 Jun;151(6):1186.e1-9.

Enrollment: 6,560 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized with non-ST elevation acute coronary syndrome
• Ischemic symptoms (more than or equal to 5 minutes) at rest within 48 hours of study entry
• At least one additional risk factor (e.g., elevated cardiac enzymes, ST-depression, diabetes)

Exclusion criteria

• Persistent acute ST-segment elevation
• Successful revascularization during the qualifying hospitalization, prior to study entry
• Acute pulmonary edema, hypotension, or evidence of cardiogenic shock
• Clinically significant liver disease
• End stage kidney disease requiring dialysis
• Concomitant use of drugs known to prolong the QT interval, or any digitalis drugs
• Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4
• Pregnant or lactating women, or women of child bearing potential not using an acceptable form of birth control

Additional study entry criteria will be evaluated during initial screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

6,560 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Ranolazine

Treatment:

Drug: Ranolazine

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo